https://www.selleckchem.com/
group 2 3.74 ± 2.42; P 0.0001). There were no differences between the groups in visual acuity and OCT thickness at 1-year follow-up. Combination therapy of topical NSAIDs with intravitreal anti-VEGF did not show any beneficial effects in terms of visual outcomes, reduction in central subfoveal thickness, or reduction in the mean number of injections in our study. Combination therapy of topical NSAIDs with intravitreal anti-VEGF did not show any beneficial effects in terms of visual outcomes, reduction in central subfoveal thickness, or reduction in the
Like
Comment
Share
